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In summary, based on our study, we still believe that con-
ventional Hemashield collagen impregnated Dacron patches,
used with carotid endarterectomy, likely carry higher periopera-
tive carotid thrombosis and stroke rates than PTFE or saphenous
vein patch. Further long-term studies are indicated if this patch is
to be used in the future. Perhaps the Finesse Hemashield patch
may prove to be a better alternative for those who prefer not to
use PTFE patches.
Ali F. AbuRahma, MD
Robert C. Byrd Health Sciences Center
West Virginia University
Charleston, WVa
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Regarding “Heparin modulates integrin function in
human platelets”
Sobel et al elegantly and convincingly show that unfraction-
ated heparin (UH) binds to the platelet integrin αIIbβ3 (Gp
IIb/IIIa).1 This binding then induced aggregation by outside-in
signaling. A few additional comments are of relevance.
The effect of UH on platelets is not uniform. UH is a more
powerful stimulator of in vitro and ex vivo aggregation in situa-
tions where platelet hyperactivity is present (eg, peripheral vascu-
lar disease,2 coronary artery disease,3,4 and anorexia nervosa2).
The stimulatory effect depends on which anticoagulant prepara-
tion is used. Low molecular weight heparin(oid)s (LMWH) are
less powerful stimulators than UH.5-8 Moreover, porcine mucosa
UH (used by Sobel et al) is a less powerful stimulator of aggre-
gation than bovine lung UH.5
The UH effect on aggregation is enhanced by fibrinogen
added in vitro.7 This finding may be relevant because UH
increases fibrinogen binding to platelets.1
UH also affects an early stage of platelet aggregation—the
shape change.8,10
Regarding “Prospective randomized study of carotid
endarterectomy with PTFE versus collagen
impregnated Dacron (Hemashield) patching:
Perioperative (30-day) results”
I read Dr James Edwards’ comments (J Vasc Surg
2002;35:176-7) on our paper, “Prospective randomized study of
carotid endarterectomy with PTFE versus collagen impregnated
Dacron (Hemashield) patching: Perioperative (30-day) results” (J
Vasc Surg 2002;35:125-30)1 with great interest, and I appreciate
the opportunity to respond.
Dr Edwards cited other reasons to explain the better out-
come of PTFE in regards to perioperative carotid thrombosis and
stroke, and the incidence of early (>50%) restenosis, other than
increased thrombogenecity of the Hemashield patch. We did not
conclude in our article that this was the only possible reason for
the thrombosis, and we have no explanation for these higher rates
of thrombosis and stroke. We simply raised the question as to
whether the Hemashield patch, impregnated with collagen, can
be thrombogenic in this location. This issue should be addressed
by future studies.
We would also like to point out to the readers that not all col-
lagen impregnated Dacron patches are the same as the conven-
tional Hemashield type that was used in our study. In the last few
years, a few authors, particularly surgeons in Europe, have
reported using the Finesse Hemashield with satisfactory results.2
The Finesse Hemashield has a different thickness from the con-
ventional Hemashield, which has been used in many medical cen-
ters in the USA over the last several years.
Dr Edwards also stated that the technical performance, pre-
operative antiplatelet/anticoagulation medication, patient selec-
tion, and statistical aberrancy might explain the results of the
superiority of PTFE versus Dacron. We agree that these are pos-
sibilities but don’t feel that technical performance was a factor in
this study because the two surgeons who contributed to this study
(AFA and JHK) have performed a few thousand carotid
endarterectomies over the last 20 years. The senior author (AFA)
has reported the results of carotid endarterectomy in two ran-
domized trials over the last several years using patch materials
other than Hemashield, such as saphenous vein, internal jugular
vein, or PTFE patching, with a perioperative stroke rate of
0.9%.3,4 The routine protocol used for this study was similar to
what has been used over the last 20 years and has been published
previously.3 However, it’s conceivable that a statistical error may
have been a factor in this study because of the sample size (200),
even though we exceeded the required sample size recommended
by our statistician.
Dr Edwards also indicated that the 5% acute carotid occlu-
sion rate was quite unusual. We agree with him, and as a matter
of fact, it was surprising to us. If you take the senior surgeon’s
(AFA) experience, the perioperative occlusion rate in this study
was 3 out of 90 (3.3%) in the Hemashield patch group, which is
relatively close to what has been reported by others (close to 2%,
as reported by Ricco et al2). Our perioperative carotid occlusion
rate in past endarterectomy trials has been <1%, which is similar
to that reported by Dr Edwards’ group, but different patches
were used in these (eg, saphenous vein or PTFE).
These features are relevant to the phenomenon of UH-
induced platelet activation because of the following.
1. UH is used in patients with vascular disease. As Sobel et al1
point out, platelet activation in these patients is undesirable.
The clinical and experimental situations described above pro-
vide an opportunity to assess the clinical relevance of direct
UH-induced platelet activation.
2. The findings described above provide models where the mo-
lecular basis of the mechanism described by Sobel et al1 can
be assessed. For example, it is expected that LMWH will bind
less to Gp IIb/IIIa than UH. Similarly, UH binding and/or
outside-in signaling should be enhanced in patients with
peripheral vascular disease, especially if they demonstrate
platelet hyperactivity.
Direct platelet activation by UH may reduce the benefit
accrued from the use of this anticoagulant. This concept is likely
to be further clarified now that Sobel et al1 have worked out the
process of direct UH-induced platelet activation.
D. P. Mikhailidis, MD, FACA, FACB, FRCPath
I. A. Jagroop, BSc (Hons), MPhil
Cardiovascular Disease Prevention Clinics
Department of Clinical Biochemistry
Royal Free and University College Medical School
University of London
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Regarding “The 50th anniversary of abdominal
aortic reconstruction”
In his historical review of abdominal aortic reconstruction (J
Vasc Surg 2001;33:895-8), Dr Friedman has written a tribute of
Dubost and Oudot with empathy, but, to quote Goethe, “Often
when primacy is claimed, the pleasure of discovery is spoiled
because we are not the first.” Their excellent work1 has been well
recognized, while that of Freeman,2 who preceded them, has
been ignored, except by Bergan.3
Many surgeons, on returning home at the end of World War
II, found conditions ideal for laboratory and clinical research. The
scene was thus set for the explosive development of vascular
surgery during its golden decade (1946-1956). In San Francisco,
at the medical school of the University of California, a small
group (Gilfillan, Wylie, and Leeds) commenced, under the guid-
ance of Dr Freeman, to work on various problems in vascular
surgery. These were wonderful years, filled with the joy of learn-
ing, but we soon found out that there is no easy road to first dis-
coveries. As F. Paiz expresses it, “Traveler, there is no path, the
path is made by walking.”
Dr Freeman asked me to study (1) the possibility of de-
veloping an experimental model of aneurysm and (2) the
bursting pressures of arteries and veins. At that time, in our
operative approach to abdominal aortic aneurysms, we had
tried ligation, wiring, and cellophane wrapping, but the results
and complications were discouraging. As the data on bursting
pressures in the experimental animal suggested that the 
iliac vein would withstand arterial pressures, on February 12,
1951, we resected an aneurysm and replaced it with a vein
graft taken from the patient’s left common iliac vein and 
its bifurcation. Six hours postoperation the patient died. We
were unable to obtain an autopsy, but the sudden death, we
felt, was due to rupture of the vein graft. Therefore, 
on February 26, 1951, when we were presented with a 55-
year-old man with a large symptomatic aneurysm, Freeman
modified the operation by opening the aneurysm longitudi-
nally, and a vein graft, consisting of the patient’s left common
iliac vein and its bifurcation, was sutured within the aneurys-
mal sack to the aorta and iliac arteries. The aneurysmal sack
was then closed around the graft.
The 15-month follow-up, including an aortogram at 4
months, showed an excellent result. This case was presented at
the first meeting of the International Society of Angiology (now
the American Association for Vascular Surgery) on June 9, 1951,
and published in Angiology in December 1951.4
The obvious problem with this technique was the extra time
and trauma needed to obtain the autologous graft. A cadaver
graft seemed the solution, but Freeman, on the basis of earlier
studies,5 refused to consider it, as he felt a homologous graft
would not hold up over time.
Then in June of 1952, Freeman returned from a trip to the
East Coast with the exciting news of Voorhees’ dramatic break-
through6 and a piece of Vinyon-N cloth, given to him by
Blakemore, and aortic aneurysm surgery was really on its way, for
now we had a readily available graft for the inlay technique, which
was used, from then on, by Freeman and myself and was eventu-
ally popularized by Creech.7 Our inlay technique was a simpler
one than the excisional one, later developed by Dubost, which
required “a sometimes difficult and hazardous dissection.”
This explosive development in vascular surgery was not local-
ized, but generalized throughout Europe and America. Should
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